Condition: Resectable NSCLC · KRAS G12C Mutation · Stage IB-IIIA NSCLC · Sponsor: Jianxing He
This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation. Approximately 30 treatment-naïve patients with stage IB-IIIA (AJCC 8th edition) NSCLC and confirmed KRAS G12C mutation will be enrolled. Eligible subjects will receive 6 weeks of fulzerasib followed by a 2-week washout period, then 3 cycles (q3w) of sintilimab plus investigator's choice of platinum-doublet chemotherapy. An end-of-treatment visit will be performed within 7 days after the last dose of neoadjuvant therapy.
This description comes directly from the study's public registry record.
WENHUA LIANG, M.D. · +86-20-8337792 · liangwh1987@163.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital of Zhejiang University School of Medicine | Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07492342